miércoles, 12 de diciembre de 2018

Treatments of Primary Basal Cell Carcinoma of the Skin: A Systematic Review and Network Meta-analysis. - PubMed - NCBI

Treatments of Primary Basal Cell Carcinoma of the Skin: A Systematic Review and Network Meta-analysis. - PubMed - NCBI

AHRQ News Now

AHRQ Study Reaffirms Success of Surgery, External-Beam Radiation To Treat Basal Cell Carcinoma

Surgery and external-beam radiation help keep a common nonmelanoma skin cancer from returning, but evidence is insufficient to compare them with other treatments, according to a recent Annals of Internal Medicine article based on an AHRQ systematic review. Researchers analyzed the effectiveness and safety of treatments for basal cell carcinoma, the most common cancer in the United States, including topical treatments such as gel or cream, surgical removal, external-beam radiation and other procedures, like Mohs surgery and curettage and diathermy, cryotherapy and photodynamic therapy. The authors noted that the American Academy of Dermatology has called for more evidence on comparative effectiveness of treatments. The authors found that evidence also is lacking for treatments of more aggressive types of basal cell carcinoma. They suggested that better data collection by such entities as the National Cancer Institute’s Surveillance, Epidemiology, and End Results (SEER) Program or large health organizations would help prioritize research. Access the journal abstract and AHRQ’s systematic review

 2018 Oct 2;169(7):456-466. doi: 10.7326/M18-0678. Epub 2018 Sep 18.

Treatments of Primary Basal Cell Carcinoma of the Skin: A Systematic Review and Network Meta-analysis.



Most interventions for basal cell carcinoma (BCC) have not been compared in head-to-head randomized trials.


To evaluate the comparative effectiveness and safety of treatments of primary BCC in adults.


English-language searches of MEDLINE, Cochrane Central Register of Controlled Trials, Cochrane Database of Systematic Reviews, and Embase from inception to May 2018; reference lists of guidelines and systematic reviews; and a search of ClinicalTrials.gov in August 2016.


Comparative studies of treatments currently used in adults with primary BCC.


One investigator extracted data on recurrence, histologic clearance, clinical clearance, cosmetic outcomes, quality of life, and mortality, and a second reviewer verified extractions. Several investigators evaluated risk of bias for each study.


Forty randomized trials and 5 nonrandomized studies compared 18 interventions in 9 categories. Relative intervention effects and mean outcome frequencies were estimated using frequentist network meta-analyses. Estimated recurrence rates were similar for excision (3.8% [95% CI, 1.5% to 9.5%]), Mohs surgery (3.8% [CI, 0.7% to 18.2%]), curettage and diathermy (6.9% [CI, 0.9% to 36.6%]), and external-beam radiation (3.5% [CI, 0.7% to 16.8%]). Recurrence rates were higher for cryotherapy (22.3% [CI, 10.2% to 42.0%]), curettage and cryotherapy (19.9% [CI, 4.6% to 56.1%]), 5-fluorouracil (18.8% [CI, 10.1% to 32.5%]), imiquimod (14.1% [CI, 5.4% to 32.4%]), and photodynamic therapy using methyl-aminolevulinic acid (18.8% [CI, 10.1% to 32.5%]) or aminolevulinic acid (16.6% [CI, 7.5% to 32.8%]). The proportion of patients reporting good or better cosmetic outcomes was better for photodynamic therapy using methyl-aminolevulinic acid (93.8% [CI, 79.2% to 98.3%]) or aminolevulinic acid (95.8% [CI, 84.2% to 99.0%]) than for excision (77.8% [CI, 44.8% to 93.8%]) or cryotherapy (51.1% [CI, 15.8% to 85.4%]). Data on quality of life and mortality were too sparse for quantitative synthesis.


Data are sparse, and effect estimates are imprecise and informed by indirect comparisons.


Surgical treatments and external-beam radiation have low recurrence rates for the treatment of low-risk BCC, but substantial uncertainty exists about their comparative effectiveness versus other treatments. Gaps remain regarding high-risk BCC subtypes and important outcomes, including costs.


Agency for Healthcare Research and Quality. (PROSPERO: CRD42016043353).


No hay comentarios: